




Investor Presentation

September 2024

Forward Looking Statements

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any “phase” of clinical trials. We also cannot be sure of the clinical outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.

**We are Dedicated to
Pushing the Boundaries of
Scientific Discovery With
Novel Oral Small Molecules
Tailored to Potentially Offer
Hope and Relief.**



Worldwide Alzheimer's - Dementia Cases Projected to Grow to Over 130M by 2050

We believe we are positioned to capitalize on a significant and growing market opportunity to treat CNS diseases

>\$20T

Cumulative costs of Alzheimer's and dementia care from 2015 to 2050

1 in 3


Medicare dollars will be spent on people living with Alzheimer's and other dementias in 2050

>11M


The number of Americans providing unpaid care for people with Alzheimer's or other dementias

Targeting these markets using a differentiated and transformative precision platform

PEOPLE LIVING WITH DEMENTIA AROUND THE WORLD



Anavex Investment Highlights



Wide international patent protection for product candidates



Regulatory submission stage CNS Precision Medicine platform Company with novel central nervous system mechanism



Meet with regulatory authorities to discuss full Phase 2b/3 Alzheimer's data with aim to bring Alzheimer's therapy to patients in Europe, Asia-Pacific, and the U.S., including potential approval pathway based on available efficacy results of surrogate biomarkers



Estimated that operations and clinical programs are funded for 4 years. No debt



Oral drug Blarcamesine demonstrated superior clinical safety and efficacy compared to mAb Leqembi (Lecanemab) and mAb Donanemab and slows neurodegeneration in Early Alzheimer's Disease^{1,2,3}

Blarcamesine: Oral once daily convenient scalable treatment

1. <https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdisease>
2. van Dyck CH et al. Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*. 2023; 388(1): 9–21
3. Sims JR et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. 2023; 330(6): 512–27

Foundation for More Cost Effective & Safer Treatments for CNS Conditions

Oral Solid ANAVEX®2-73 (blarcamesine)

- Alzheimer's Disease
- Parkinson's Disease
- Parkinson's Disease Dementia



Oral Liquid ANAVEX®2-73 (blarcamesine)

- Rett Syndrome
- Fragile X Syndrome
- Infantile Spasms
- Angelman Syndrome



Oral Solid ANAVEX®3-71 (AF710B)

- Schizophrenia
- Frontotemporal Dementia (FTD)
- Alzheimer's Disease



Orally-administered candidates offer significant potential for clinical benefit relative to costly and logistically challenging biologic mAb-based drugs, which also often present additional safety challenges

~60%

of established small-molecule drug products available commercially are administered orally¹

~90%

of the global market share of all pharmaceutical formulations for humans are oral¹

~84%

of the best-selling pharmaceutical products are orally administered¹

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease



We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Anavex Precision Platform Enables a Novel Approach

Targeting CNS conditions with precision and **restoring neuronal homeostasis** via **SIGMAR1 activation**

Proprietary SIGMACEPTOR™ Discovery Platform produces small molecule therapeutic candidates for targeting the SIGMAR1 receptor

Age- and chronic related Changes

Chronic CNS pathologies, including progressive chronic Alzheimer's, cause exhaustion of the body's own SIGMAR1 activators, impairing the body's response to chronic cellular stress

Progressive CNS Pathology (e.g., AD, PD)

Impaired body-own compensatory SIGMAR1 response to chronic cellular stress

ANAVEX®2-73 (blarcamesine)

ANAVEX®2-73 (blarcamesine) re-establishes the body's own SIGMAR1 response and restores SIGMAR1 levels

Beneficial therapeutic effect for patients


SIGMAR1 target binding affinity is so specific that even when patients carry a variant receptor, still powerful effects observed. All patients regardless of genotype stand to benefit

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD




Autophagy: An Upstream Compensatory Therapeutic Intervention in AD




Autophagy: An Upstream Compensatory Therapeutic Intervention in AD

Blarcamesine
(oral drug)



Christ, M G et al. "Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo." *Cells* vol. 8,3 211. 2 Mar. 2019. doi:10.3390/cells8030211

Autophagy: An Upstream Compensatory Therapeutic Intervention in AD



Christ, M G et al. "Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo." *Cells* vol. 8,3 211. 2 Mar. 2019. doi:10.3390/cells8030211

Precision Platform Shows Promise for Superior Care

We believe Anavex is positioned to target significant unmet medical needs across multiple CNS conditions



Achieved



Near Term



Long Term

SIGMAR1 activation established as a new platform class

- ANAVEX[®]2-73 (blarcamesine)**
Clinical study results in broad CNS indications confirm SIGMAR1 technology
- Rett syndrome:** Top-line data EXCELLENCE Phase 2/3 ANAVEX[®]2-73 pediatric clinical trial
- ANAVEX[®]3-71:** Publication Phase 1 clinical trial
- Parkinson's disease dementia:** Data of 48-week OLE Phase 2 study
- Alzheimer's disease:** Top-line data ANAVEX[®]2-73-AD-004: Potentially pivotal Phase 2b/3 clinical trial
- Schizophrenia:** Initiation of ANAVEX[®]3-71 Phase 2 clinical trial

SIGMAR1 technology to succeed traditional modalities

- Alzheimer's disease:** Data from the blarcamesine Phase 2b/3 ANAVEX[®]2-73-AD-004 trial to be published in an upcoming peer-reviewed journal
- Alzheimer's disease:** Full regulatory submission of blarcamesine in Europe (EMA)
- Alzheimer's disease:** Analysis of RNA sequencing (RNA-seq) of the Phase 2b/3 data expected 2H 2024
- Alzheimer's disease:** Ongoing ATTENTION-AD OLE 96-week trial data expected 2H 2024
- Schizophrenia:** Top-line data of ANAVEX[®]3-71 Phase 2 clinical trial
- Parkinson's disease:** Initiation of ANAVEX[®]2-73 imaging-focused trial or Phase 2b/3 >6 months trial
- Fragile X:** Initiation of ANAVEX[®]2-73 Phase 2/3 clinical trial
- New Rare disease:** Initiation of ANAVEX[®]2-73 Phase 2/3 clinical trial
- Publications:** Continued clinical publications involving ANAVEX[®]2-73 and ANAVEX[®]3-71

SIGMAR1 to potentially open up new opportunities beyond the horizon

- Expanded CNS indications
- Regenerative medicine¹
- Disease prevention²

1. K. Ruscher, T. Wieloch, *The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration*, *Journal of Pharmacological Sciences*, Volume 127, Issue 1, 2015, Pages 30-35, ISSN 1347-8613, <https://doi.org/10.1016/j.jpsh.2014.11.011>.

2. L. Nguyen et al., *Role of sigma-1 receptors in neurodegenerative diseases*, *Journal of Pharmacological Sciences*, Volume 127, Issue 1, 2015, Pages 17-29, ISSN 1347-8613, <https://doi.org/10.1016/j.jpsh.2014.12.005>.

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease




We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Multiple Clinical Milestones and Promising Pipeline with Potential Progress towards Commercialization

| CANDIDATE | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | PHASE 4 | |
|--|--------------------------------|-------------------------------|--------------------|---------------------------|---|--|
| ANAVEX®2-73 <i>blarcamesine</i>  | ALZHEIMER'S DISEASE | AD ANAVEX®2-73-AD-004 | | AD ANAVEX®2-73-AD-004 OLE | | |
| | PARKINSON'S DISEASE DEMENTIA | ANAVEX®2-73-PDD-001 | | | | |
| | PARKINSON'S DISEASE | ANAVEX®2-73-PET-001 | | ANAVEX®2-73-PD-001 | | |
| | *RETT SYNDROME | EXCELLENCE ANAVEX®2-73-RS-003 | | | ANAVEX®2-73-RS-003 OLE / COMPASSIONATE USE | |
| | *RETT SYNDROME | AVATAR ANAVEX®2-73-RS-002 | | | ANAVEX®2-73-RS-002 OLE / COMPASSIONATE USE | |
| | *RETT SYNDROME | ANAVEX®2-73-RS-001 | | | Fast Track, Rare Pediatric, Orphan Drug (U.S./EU) | |
| | UNDISCLOSED RARE DISEASE | | | | | |
| | *FRAGILE X | | | | | |
| | ANGELMAN'S | | | | | |
| | *INFANTILE SPASMS | | | | | |
| ANAVEX®3-71 <i>AF710B</i> | SCHIZOPHRENIA | ANAVEX®3-71-001 | ANAVEX®3-71-SZ-001 | | | |
| | *FRONTOTEMPORAL DEMENTIA (FTD) | ANAVEX®3-71-001 | | | | |
| | ALZHEIMER'S DISEASE | ANAVEX®3-71-001 | | | | |
| ANAVEX®1-41 | DEPRESSION | | | | | |
| | STROKE | | | | | |
| | NEURODEGENERATIVE DISEASES | | | | | |
| ANAVEX®1066 | VISCERAL PAIN | | | | | |
| | ACUTE & NEUROPATHIC PAIN | | | | | |

Legend

- Solid color = completed
- Gradient color = ongoing
- Dashed lines = planned

* Orphan Drug Designation by FDA

Treating Alzheimer's Disease (AD)

Progressive, neurological disease and the most common cause of dementia in humans¹







- Progressive development; slowly destroys memory and thinking skills in people
- **Impacts families** and nearly **every aspect** of a person's life as it progresses: short-term memory loss and confusion, difficulty learning new things, delusions and disorientation, inability to recognize common things in people
- Current annual cost of dementia is estimated at \$1T, a figure set to double by 2030

~35M

people worldwide living with AD²

~6.9M

people in the U.S. living with AD²

| CANDIDATE | STAGE 1 | STAGE 2 | STAGE 3 | STAGE 4 |
|--|---|---|---|---|
| ANAVEX [®] 2-73 (blarcamesine) |  ANAVEX [®] 2-73-001 |  AD ANAVEX [®] 2-73-002/3 |  AD ANAVEX [®] 2-73-004 |  (Ongoing EMA) |
| ANAVEX [®] 3-71 |  ANAVEX [®] 3-71-001 |  (Planned Trial) | | |


1. Source: www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia

2. Sources available on slide 28 of this presentation.

Treating Parkinson's Disease (PD) & Parkinson's Disease Dementia (PDD)

Motor disorder in which patients suffer from tremors in their extremities and head, stiff limbs and inability to relax muscles during episodes

- Up to 80% of those with Parkinson's disease (PD) eventually experience Parkinson's disease dementia¹
- Progressive development; can cause numerous cognitive and behavioral deficits
- Parkinson's disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2% of those over the age of 65



>1%
of the world population has PD²

>1.5M
Americans affected by
PD today²

| | CANDIDATE | STAGE 1 | STAGE 2 | STAGE 3 |
|-------------------------------------|---|------------------------------|--------------------------------------|-----------------|
| PARKINSON'S DISEASE | ANAVEX [®] 2-73 (blarcamesine) | ANAVEX [®] 2-73-001 | (Planned Trial) | (Planned Trial) |
| PARKINSON'S DISEASE DEMENTIA | ANAVEX [®] 2-73 (blarcamesine) | ANAVEX [®] 2-73-001 | PDD ANAVEX [®] 2-73-PDD-001 | (Planned Trial) |



1. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. *Nat Rev Neurol.* 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. PMID: 28257128; PMCID: PMC5643027;
2. www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia

Treating Rett Syndrome

Neuro-developmental disease in girls with both movement impairment and cognitive impairment¹

- Second most common cause of severe intellectual disability in females
- Cognitive and motor delays begin to manifest along with slower head growth following relatively normal infancy (~1.5 to 3 years of age, loss of spoken language, and hand skills begin to develop)
- Associated with four key symptoms: **loss of expressive language, loss of fine motor skills, impaired ability to walk and repetitive hand movement**










~350,000

patients diagnosed with Rett Syndrome worldwide¹

~11,000

patients diagnosed with Rett Syndrome in the U.S.²

| CANDIDATE | STAGE 1 | STAGE 2 | STAGE 3 |
|--|---|--|--|
| ANAVEX [®] 2-73 - Pediatrics (blarcamesine) |  ANAVEX [®] 2-73-001 |  EXCELLENCE ANAVEX [®] 2-73-RS-003 |  (Planned Trial) |
| ANAVEX [®] 2-73 - Adults (blarcamesine) |  ANAVEX [®] 2-73-001 |  U.S. ANAVEX [®] 2-73-RS-001 | |
| ANAVEX [®] 2-73 - Adults (blarcamesine) |  ANAVEX [®] 2-73-001 | |  AVATAR ANAVEX [®] 2-73-RS-002 |

1. Source: <https://www.rett syndrome.org/about-rett-syndrome>.

2. Sources available on slide 28 of this presentation.

Real World Evidence (RWE): Patients with Rett Syndrome Positive Feedback with Blarcamesine

Voice of the Patients: Real World Evidence (RWE)

- Brigitte: “*We did get a surprise once with her mobility. We heard a noise from our family room, and next we looked, and Madeline had climbed twelve steps upstairs to her bedroom by herself.*”
- Jayne: “*Within a week of starting the Anavex open label extension, she only had one seizure and then she went three months without a seizure.*”
- See related link for more video comments from parents at [RSAA/parent stories](#).
- >91% of patients completing the EXCELLENCE trial continued into a 48-week open-label extension study (OLE)
- To date, of the pediatric patients who completed the OLE, 93% have joined the Compassionate Use Program
- Compassionate Use level for adult patients from AVATAR trial after 48-week OLE is >96%
- As of today, some patients with Rett syndrome have been **on blarcamesine-treatment for >4 years**, combined OLE and Compassionate Use Program

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease




We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

AD-004 Phase 2b/3 Early Alzheimer's Disease Trial

Global, multicenter, randomized, double-blind, placebo-controlled, parallel group, 48-week trial evaluating Blarcamesine (ANAVEX[®]2-73) once-daily oral capsules



Key eligibility criteria:

- Met the NIA-AA 2011 criteria for diagnosis of early-stage mild dementia or MCI due to AD
- Aged 60 to 85 years
- MMSE score 20-28
- Confirmation of AD via amyloid or FDG PET, CT or MRI scan, or CSF (amyloid or tau)¹

Co-primary endpoints*

- ADAS-Cog13
- ADCS-ADL

Other endpoints

- Structural and functional MRI
- Biomarkers: A β_{42} /A β_{40} , p-tau (181), p-tau (231), Nf-L
- CGI-I

Key secondary endpoint

- CDR-SB

ATTENTION-AD study

*With the March 2024 FDA Guidance for Early AD, a sole cognitive measure can serve as the primary endpoint for early AD trials

1. AD status supported by the elevated baseline levels of plasma p-Tau(181) and p-Tau(231)


2. Titration occurred from days 1-21

Alzheimer's Disease Pathology Manifested in Brain Volume Loss (Atrophy) of the Brain

Brain volume loss (atrophy) in Alzheimer's disease (AD)¹



NORMAL




AD

1. Exemplified by [defying dementia lancaster.ac.uk/defyingdementia](http://defyingdementia.lancaster.ac.uk/defyingdementia)

Reduced Atrophy of the Brain in Blarcamesine-treated Patients Compared to Placebo

Significant slowing of atrophy in broad brain regions after 48 weeks of treatment¹

$p < 0.05$ $p < 0.0001$



1. <https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimersdisease>

Anavex's Blarcamesine Advantage:

- ✓ Oral administration
- ✓ Novel target that impacts neurodegeneration
- ✓ Promising clinical results



We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease




We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Exploring Commercial Activities

Examining innovative strategies to effectively engage patients, providers and payers



High demand from Alzheimer's disease patients and families for easy access and scalable treatment options

Intended to reduce the need for complex procedures for the treatment of people with Alzheimer's disease

Blarcamesine orally once daily versus challenges of biologic mAb-based intravenous drug

Addressable CNS Diseases Globally with Therapeutic Disruption Potential

U.S. AND GLOBAL PATIENT NUMBERS

| INDICATION | USA | EUROPE | ASIA | GLOBAL |
|--|------------|------------|-------------|-------------|
| Alzheimer's Disease (AD) ^{1,2} | ~6,900,000 | ~7,800,000 | ~23,000,000 | ~35,000,000 |
| Parkinson's Disease (PD) ^{3,4} | ~1,000,000 | ~1,400,000 | ~3,000,000 | ~10,000,000 |
| Schizophrenia ^{5,6*} | ~1,600,000 | ~3,000,000 | ~9,000,000 | ~24,000,000 |
| Frontotemporal Dementia (FTD) ⁷ | ~60,000 | ~65,000 | ~500,000 | ~800,000 |
| Rett Syndrome (RTT) ^{8*} | ~11,000 | ~13,000 | ~37,000 | ~350,000 |
| Fragile X Syndrome (FXS) ^{9,10*} | ~62,500 | ~150,000 | ~900,000 | ~1,400,000 |

1. Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures

2. *Dementia in the Asia Pacific Region. Alzheimer's Disease International 2014; 10*

3. Marras C et al 2018. *npj Parkinson's Disease volume 4, Article number: 21*

4. *GBD 2016 Parkinson's Disease Collaborators. The Lancet 2018 Volume 17, Issue 11, P3939-953*

5. *National Alliance on Mental Illness, 2019; Schizophrenia. World Health Organization. Accessed January 2024. <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>*

6. Fasseh et al., 2018. *Eur J Public Health. 2018 Dec 1;28(6):1043-1049*

7. Knopman & Roberts 2011. *J Mol Neurosci 2011;45(3):330-335*

8. *Rettsyndrome.org, 2016*


9. *National Fragile X Foundation, 2022*

10. Hunter et al., 2014. *Am J Med Genet A. 2014 Jul;164A(7):1648-5*

* Patient estimates derived from the published prevalence estimate range for the regional population

Worldwide Commercial Rights to Capitalize on Valuable Pipeline and Global Opportunity

Aiming to bring lead therapies to patients in Europe, Asia-Pacific, and the U.S. following regulatory discussion



Wide international patent protection to 2030-2039 for product candidates

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease



We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government

Anavex's Strong Financial Profile Supports Operations and Clinical Programs are Funded for 4 Years

Strong balance sheet supported by non-dilutive funding sources



\$138.8M

Cash and cash equivalents¹



~84M

Shares outstanding¹

Non-dilutive funding sources



Disciplined approach to operational expenditures



27.8M

Fiscal year 2023 cash utilization

Sufficient cash runway



4

Est. Years of Runway

Sustainable cash runway due to disciplined operations and non-dilutive cash sources

1. As of June 30, 2024

Values-Driven Team with Track Record and Expertise Capable of Advancing Anavex's Cutting-Edge Precision Platform

Christopher U. Missling, PhD

President & CEO

20+ years of experience in the healthcare industry within large pharmaceutical companies, the biotech industry and investment banking



Juan Carlos Lopez-Talavera, MD, PhD

SVP Head of Research and Development

25+ years of key leadership in managing registrational clinical trials and led and contributed to the development and approvals of several treatments in USA, Europe and Asia



Terrie Kellmeyer, PhD

SVP of Clinical Development

28+ years of experience in executive leadership positions in clinical development, clinical operations, regulatory affairs, and medical affairs



Jeffrey Edwards, PhD

VP of Clinical Pharmacology

18+ years of drug development including clinical pharmacology and clinical science



Kun Jin, PhD

VP Head of Biostatistics

27+ years of experience with US Food and Drug Administration (FDA)



Daniel Klamer, PhD

VP of Business Development & Scientific Strategy

15+ years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA



Purpose-Built Scientific Advisory Board

Diverse skillset tailored to Anavex's portfolio



CNS Drug development



Trial design and analysis



Academic and research thought leadership



Clinical expertise in treating CNS diseases

Andrew Cole, MD



Corinne Lasmezas, PhD



Dag Aarsland, MD, PhD



Daniel Weintraub, MD



Jacqueline French, MD



Jeffrey Cummings, MD



Norman Relkin, MD, PhD



Ottavio Arancio, MD, PhD



Paul Aisen, MD



Tangui Maurice, PhD



Timo Grimmer, MD




Marwan Sabbagh, MD



**Anavex's Advantage is
Precision Medicine Platform
Scalability**

**Equitable and Accessible
for Diverse Populations, and
Maintaining Sustainability
within Global Healthcare
Systems**



Contact Us

Corporate Office

Anavex Life Sciences Corp.
630 5th Avenue, 20th floor
New York, NY 10111

1-844-689-3939

Shareholder & Media Relations

ir@anavex.com
www.anavex.com

NASDAQ: AVXL